C
53.66
-1.96 (-3.52%)
| Previous Close | 55.62 |
| Open | 55.53 |
| Volume | 676,883 |
| Avg. Volume (3M) | 726,930 |
| Market Cap | 4,976,299,520 |
| Price / Sales | 4.32 |
| Price / Book | 6.70 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Operating Margin (TTM) | -29,525.22% |
| Diluted EPS (TTM) | -3.70 |
| Quarterly Revenue Growth (YOY) | -59.60% |
| Total Debt/Equity (MRQ) | 6.31% |
| Current Ratio (MRQ) | 16.39 |
| Operating Cash Flow (TTM) | -199.81 M |
| Levered Free Cash Flow (TTM) | -115.20 M |
| Return on Assets (TTM) | -24.29% |
| Return on Equity (TTM) | -40.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Crinetics Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
2.3
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 2.25 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.80% |
| % Held by Institutions | 94.72% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 87.00 (JMP Securities, 62.13%) | Buy |
| Median | 81.00 (50.95%) | |
| Low | 74.00 (Citigroup, 37.91%) | Buy |
| Average | 80.67 (50.34%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 57.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 16 Dec 2024 | 87.00 (62.13%) | Buy | 54.63 |
| 27 Sep 2024 | 80.00 (49.09%) | Buy | 50.75 | |
| Citigroup | 14 Nov 2024 | 74.00 (37.91%) | Buy | 59.66 |
| HC Wainwright & Co. | 13 Nov 2024 | 81.00 (50.95%) | Buy | 58.92 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |